Slowly Signaling G Protein–Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and DependenceXiaoyan Lin, Andrea G. Hohmann|Molecular Pharmacology|2017Cited by 87
Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and WithdrawalAiling Li, Andrea G. Hohmann|Molecular Pharmacology|2018Cited by 68
Negative allosteric modulation of CB1 cannabinoid receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociceptionVishakh Iyer, Andrea G. Hohmann|Neuropharmacology|2024Cited by 8
Negative allosteric modulation of cannabinoid CB <sub>1</sub> receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociceptionVishakh Iyer, Andrea G. Hohmann|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 2
Mice lacking the endocannabinoid-synthesizing enzyme NAPE-PLD exhibit sex-dependent dysregulations in responsiveness to oxycodone and a natural rewardTaylor J. Woodward, Andrea G. Hohmann|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0